https://www.jnj.com/rss-feed/all.rss RSS feed all en-US Thu, 21 May 2026 11:00:06 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-advances-creation-of-global-intelligent-or-network-in-collaboration-with-department-of-health-abu-dhabi Department of Health – Abu Dhabi standardizes operating rooms on Polyphonic™ to empower clinicians and advance global AI Building on collaboration with AWS and NVIDIA, the effort expands the ecosystem of healthcare and technology leaders scaling surgical innovation Thu, 21 May 2026 11:00:06 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-advances-creation-of-global-intelligent-or-network-in-collaboration-with-department-of-health-abu-dhabi https://www.jnj.com/media-center/press-releases/groundbreaking-global-survey-captures-the-significant-patient-burden-experienced-with-current-standard-of-care-bladder-cancer-treatments-underscoring-urgency-for-continued-innovation • More than 90% of patients surveyed who underwent bladder removal or received BCG report negative impact on most aspects of their lives • Among patients treated with BCG, three-quarters describe managing the treatment-related physical symptoms as humiliating • Patients and urologists point to the importance of advancing treatments that may better reflect patient preferences and quality‑of‑life considerations Thu, 14 May 2026 20:06:43 GMT https://www.jnj.com/media-center/press-releases/groundbreaking-global-survey-captures-the-significant-patient-burden-experienced-with-current-standard-of-care-bladder-cancer-treatments-underscoring-urgency-for-continued-innovation https://www.jnj.com/media-center/press-releases/johnson-johnson-showcases-hematology-leadership-with-30-presentations-at-the-2026-european-hematology-association-eha-congress · Johnson & Johnson will present 30+ abstracts at European Hematology Association 2026, highlighting leadership in hematology with data across multiple myeloma and leukemia, and first pivotal data in warm autoimmune hemolytic anemia · Phase 3 results evaluate the potentially transformative investigational combination of TALVEY®, the first GPRC5D‑targeted bispecific antibody, in combination with DARZALEX FASPRO® with or without pomalidomide for patients with relapsed or refractory multiple myeloma in earlier lines of therapy · Pivotal Phase 2/3 results potentially position IMAAVY® as the first FDA-approved treatment for warm autoimmune hemolytic anemiaa designed to target the IgG autoantibodies responsible for red blood cell destruction Tue, 12 May 2026 20:54:53 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-showcases-hematology-leadership-with-30-presentations-at-the-2026-european-hematology-association-eha-congress https://www.jnj.com/media-center/press-releases/johnson-johnson-advances-the-standard-of-calcium-modification-with-global-launch-of-shockwave-c2-aero-coronary-ivl-catheter • Next-generation intravascular lithotripsy (IVL) catheter resets physicians’ expectations by addressing unmet needs in deliverability, lesion crossing and balloon repositioning • Shockwave C2 Aero enables clinicians to extend Shockwave IVL’s clinically-validated mechanism of action to a broader spectrum of calcified coronary lesions Tue, 12 May 2026 11:45:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-advances-the-standard-of-calcium-modification-with-global-launch-of-shockwave-c2-aero-coronary-ivl-catheter https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conference Mon, 11 May 2026 20:37:14 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conference https://www.jnj.com/media-center/press-releases/johnson-johnson-reinforces-its-leadership-in-advancing-neuropsychiatry-with-new-portfolio-and-pipeline-data-at-apa-and-ascp Oral presentations feature CAPLYTA® long-term data assessing relapse risk reduction in schizophrenia and new seltorexant analyses in major depressive disorder (MDD) with insomnia symptoms 18 abstracts highlight J&J’s leadership and deep portfolio in neuropsychiatry at the American Psychiatric Association (APA) and American Society of Clinical Psychopharmacology (ASCP) Annual Meetings Mon, 11 May 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-reinforces-its-leadership-in-advancing-neuropsychiatry-with-new-portfolio-and-pipeline-data-at-apa-and-ascp https://www.jnj.com/media-center/press-releases/johnson-johnson-launches-generation-fine-a-new-movement-encouraging-patients-to-expect-more-from-depression-treatment-and-aim-for-remission Generation Fine launches after global survey finds nearly 4 in 5 patients living with major depressive disorder don’t believe antidepressants will help them reach remission Campaign draws on expertise of Mental Health America and elevates the voices of leading mental health advocates, including Kyle Long, television studio analyst, retired National Football League (NFL) player Thu, 07 May 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-launches-generation-fine-a-new-movement-encouraging-patients-to-expect-more-from-depression-treatment-and-aim-for-remission https://www.jnj.com/media-center/press-releases/johnson-johnson-investigational-co-antibody-therapy-jnj-4804-shows-potential-to-raise-the-bar-for-clinical-efficacy-in-treating-refractory-inflammatory-bowel-disease JNJ-4804 demonstrated highest rates of clinical and endoscopic outcomes compared to golimumab and guselkumab in patients with ulcerative colitis or Crohn’s disease who have had inadequate response to two or more systemic therapy classes JNJ-4804 is the first and only fixed dose co-antibody designed to deliver molecular synergy in IBD by blocking the complementary IL-23 and TNF pathways Data from Phase 2b DUET studies show potential to address a critical unmet need and support advancement to Phase 3 trials Tue, 05 May 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-investigational-co-antibody-therapy-jnj-4804-shows-potential-to-raise-the-bar-for-clinical-efficacy-in-treating-refractory-inflammatory-bowel-disease https://www.jnj.com/media-center/press-releases/johnson-johnson-study-shows-tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-demonstrate-efficacy-in-perianal-fistulizing-crohns-disease TREMFYA® demonstrated significantly higher rates of combined fistula remission – complete external closure of draining fistulas and absence of fluid collection on MRI – compared to placebo at Week 24 First study of its kind in 20 years for this debilitating manifestation of Crohn’s disease presented as late-breaking data at Digestive Disease Week (DDW) 2026 Tue, 05 May 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-study-shows-tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-demonstrate-efficacy-in-perianal-fistulizing-crohns-disease https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-pivotal-clinical-study-results-for-a-new-soft-tissue-surgical-robotic-system Study results represent a critical milestone for the investigational OTTAVA™ Robotic Surgical System Data demonstrates feasibility of novel system architecture with table‑integrated robotic arms in space‑constrained ORs Abstract presented at the 2026 American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting Presidential Grand Round Sessions in San Antonio, Texas Tue, 05 May 2026 11:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-pivotal-clinical-study-results-for-a-new-soft-tissue-surgical-robotic-system https://www.jnj.com/media-center/press-releases/promising-data-from-us-pilot-study-shows-planned-impella-5-5-use-is-safe-and-feasible-in-non-shock-high-risk-cardiac-surgery-patients Mon, 04 May 2026 20:30:00 GMT https://www.jnj.com/media-center/press-releases/promising-data-from-us-pilot-study-shows-planned-impella-5-5-use-is-safe-and-feasible-in-non-shock-high-risk-cardiac-surgery-patients https://www.jnj.com/media-center/press-releases/caplyta-lumateperone-showed-greatest-improvement-across-key-efficacy-outcomes-among-adjunctive-mdd-treatments-in-new-network-meta-analysis CAPLYTA® ranked highest among FDA-approved adjunctive therapies across four measures of efficacy, based on indirect comparisons from placebo plus antidepressant therapy-controlled trials Among the secondary endpoints for the adjunctive MDD therapies evaluated, CAPLYTA® demonstrated no weight gain compared to placebo plus antidepressant therapy Featured in a late-breaking presentation at the 2026 NEI Spring Congress, analysis provides indirect comparisons to help inform treatment decisions in the absence of head-to-head clinical trials Mon, 04 May 2026 12:00:00 GMT https://www.jnj.com/media-center/press-releases/caplyta-lumateperone-showed-greatest-improvement-across-key-efficacy-outcomes-among-adjunctive-mdd-treatments-in-new-network-meta-analysis https://www.jnj.com/media-center/press-releases/johnson-johnson-to-present-new-data-spanning-vision-portfolio-at-arvo-2026 • Seventeen company presentations highlight breadth of vision portfolio spanning myopia control, ACUVUE contact lenses and TECNIS IOLs • Johnson & Johnson to debut new insights linking peripheral optics to functional vision Mon, 04 May 2026 11:45:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-present-new-data-spanning-vision-portfolio-at-arvo-2026 https://www.jnj.com/media-center/press-releases/stelara-pediatric-crohns-disease-fda-approval-j-j-statement Fri, 01 May 2026 20:14:25 GMT https://www.jnj.com/media-center/press-releases/stelara-pediatric-crohns-disease-fda-approval-j-j-statement https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-investigational-programs-in-large-b-cell-lymphoma Thu, 30 Apr 2026 20:30:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-investigational-programs-in-large-b-cell-lymphoma https://www.jnj.com/media-center/press-releases/johnson-johnson-appoints-ryan-koors-as-vice-president-investor-relations Thu, 30 Apr 2026 12:02:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-appoints-ryan-koors-as-vice-president-investor-relations https://www.jnj.com/media-center/press-releases/johnson-johnson-ushers-in-the-next-wave-of-innovation-in-cancer-care-with-more-than-20-clinical-and-real-world-studies-at-asco-2026 · Late-breaking Phase 3 PROTEUS data for ERLEADA® (apalutamide) selected to open the ASCO plenary, signaling a potential paradigm shift for high-risk prostate cancer in patients receiving curative-intent surgical treatment · Results from MajesTEC-9, the second positive Phase 3 study of TECVAYLI® (teclistamab-cqyv), reinforce TECVAYLI® regimens as potential new standard of care in multiple myeloma as early as second line · Pivotal OrigAMI-4 results evaluating RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) reinforce its potential to redefine treatment in advanced head and neck cancer Wed, 29 Apr 2026 12:30:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-ushers-in-the-next-wave-of-innovation-in-cancer-care-with-more-than-20-clinical-and-real-world-studies-at-asco-2026 https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-bernsteins-42nd-annual-strategic-decisions-conference Mon, 27 Apr 2026 20:33:30 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-bernsteins-42nd-annual-strategic-decisions-conference https://www.jnj.com/media-center/press-releases/fda-grants-priority-review-for-imaavy-nipocalimab-aahu-as-the-potential-first-approved-treatment-for-people-living-with-warm-autoimmune-hemolytic-anemia-waiha Priority Review is granted to medicines that may offer significant improvements in safety or effectiveness for serious conditions like warm autoimmune hemolytic anemia, a life-threatening disease in which pathogenic immunoglobulin G autoantibodies attach to and destroy red blood cells, leading to debilitating anemia IMAAVY is designed to target the underlying cause of warm autoimmune hemolytic anemia by reducing circulating immunoglobulin G, including autoantibodies, while preserving critical immune functions Pivotal study showed rapid and durable hemoglobin responsea and fatigue improvementb compared to placebo in patients with warm autoimmune hemolytic anemia Mon, 27 Apr 2026 12:18:35 GMT https://www.jnj.com/media-center/press-releases/fda-grants-priority-review-for-imaavy-nipocalimab-aahu-as-the-potential-first-approved-treatment-for-people-living-with-warm-autoimmune-hemolytic-anemia-waiha https://www.jnj.com/media-center/press-releases/fda-approves-caplyta-lumateperone-snda-with-robust-new-data-supporting-reduced-risk-of-relapse-in-schizophrenia CAPLYTA® reduced relapse risk by 63 percent, with 84 percent of patients with schizophrenia relapse-free over six months Demonstrating long-term stability and a well-established safety profile consistent with previous CAPLYTA® studies Mon, 27 Apr 2026 12:16:06 GMT https://www.jnj.com/media-center/press-releases/fda-approves-caplyta-lumateperone-snda-with-robust-new-data-supporting-reduced-risk-of-relapse-in-schizophrenia https://www.jnj.com/media-center/press-releases/johnson-johnson-enters-agreement-to-acquire-atraverse-medical Fri, 24 Apr 2026 12:30:57 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-enters-agreement-to-acquire-atraverse-medical https://www.jnj.com/media-center/press-releases/johnson-johnson-launches-landmark-head-to-head-pulsed-field-ablation-trial-in-persistent-atrial-fibrillation The PERSIGMA randomized control trial will deliver comparative evidence on the safety and effectiveness of the investigational VARIPULSE Pro and FARAPULSE1 platforms Fri, 24 Apr 2026 11:45:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-launches-landmark-head-to-head-pulsed-field-ablation-trial-in-persistent-atrial-fibrillation https://www.jnj.com/media-center/press-releases/imaavy-nipocalimab-aahu-shows-over-two-years-of-sustained-disease-control-in-a-broad-population-with-generalized-myasthenia-gravis-gmg Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ Patients achieving sustained minimal symptom expression (MSE) experienced greater improvements in quality of life than those with transient MSE in a post-hoc analysis of the Phase 3 study EPIC, the first head-to-head study of IMAAVY versus another FcRn blocker in generalized myasthenia gravis, is now enrolling participants Wed, 22 Apr 2026 12:05:00 GMT https://www.jnj.com/media-center/press-releases/imaavy-nipocalimab-aahu-shows-over-two-years-of-sustained-disease-control-in-a-broad-population-with-generalized-myasthenia-gravis-gmg https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-ce-mark-approval-for-the-new-ethicon-4000-stapler Designed to elevate the surgical experience and deliver reliable staple line integrity across a broad range of tissue thickness1* the ETHICON™ 4000 Surgical Stapler is certified for use in open and laparoscopic surgery across specialities in the European Union. • ETHICON™ 4000, the advanced surgical stapler, features ETHICON™ 3D Reloads with proprietary 3D Stapling Technology and enhanced Gripping Surface Technology to manage various tissues across specialties, including bariatric, colorectal and thoracic surgeries • 3D stapling technology is designed to optimize compression not only underneath each staple but also across staples and multiple staple lines, including both stapled and unstapled regions of the tissue2 • New ETHICON™ advanced stapling technology to be harnessed for future use on the OTTAVA™ Robotic Surgical System Wed, 22 Apr 2026 11:00:00 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-ce-mark-approval-for-the-new-ethicon-4000-stapler https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-2026-rbc-capital-markets-global-healthcare-conference Tue, 21 Apr 2026 20:23:09 GMT https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-the-2026-rbc-capital-markets-global-healthcare-conference